Pharmacovigilance – Considering Medicine Safety Across Communication Channels
Contents
What is pharmacovigilance?
Pharmacovigilance covers the detection, assessment, understanding and prevention of adverse effects and other medicine-related problems. It supports continuing oversight of medicine safety throughout the product lifecycle.
Information about an adverse event requires professional assessment. A temporal association does not establish causation. Equally, a report should not be disregarded merely because the causal relationship has not yet been established.
Why does pharmacovigilance concern marketing teams?
People may mention suspected adverse effects through telephone calls, emails, events or digital comments. Relevant information can therefore reach teams whose primary role is not medicine safety.
Marketing departments and agencies need a clear handover to the responsible safety function. Their role is not to perform the final medical assessment. They need to recognize potentially relevant information and forward it according to the applicable procedures.
How should communication channels be included?
Before a service launches, responsibilities and workflows should be agreed with the pharmacovigilance function.
- Map channels: Include company websites, managed social media, events and contacts handled by service providers.
- Assign ownership: Identify who recognizes information, transfers it and coordinates subsequent questions.
- Train teams: Prepare employees and contracted providers using realistic contact scenarios.
- Record handover: Use a secure, traceable process to deliver relevant information to the responsible specialists.
Specific monitoring and reporting obligations depend on the channel, organizational role and applicable rules. Deadlines should be established through the safety process rather than inferred from ordinary campaign response times.
What challenges arise in digital communication?
Posts may be incomplete, ambiguous or publicly visible. Teams need to balance appropriate follow-up with protection of personal information. Public replies should not invite unnecessary disclosure of sensitive details.
Moderation and safety handling are also different tasks. Removing a comment does not automatically complete the pharmacovigilance activity behind it. With external providers, contractual responsibilities, availability and handover routes need to fit together. A communication plan should account for these tasks even when a campaign is expected to generate little feedback.
Which details help a safety report?
Minimum criteria for a valid individual case report include an identifiable reporter and patient, a suspected medicine and a suspected adverse reaction. The safety function assesses whether these criteria are met and what follow-up is needed. Marketing teams should also forward incomplete information under the agreed procedure. Personal health details belong in appropriate protected channels rather than public requests.
Conclusion: Medicine safety depends on dependable handovers
Pharmacovigilance matters at communication touchpoints as well as within specialist teams. Training, clear responsibilities and secure forwarding support the safety function. A well-planned communication channel includes these arrangements before it goes live.
